# Cannabis News and Regulatory Roundup: Pharmacovigilance in medical cannabis therap… > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-news-and-regulatory-roundup-pharmacovigilance-in-medical-cannab-sep-2026/ > **Published:** 2026-09-25T17:41:27-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:06-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic This curated cannabis news and regulatory roundup delivers practical physician analysis of 3 timely investigations. By reviewing primary study cohorts, including Pharmacovigilance in medical cannabis therapy among physicia, healthcare providers and patients can observe reproducible trends in therapeutic use, adverse exposure patterns, and pharmacological mechanisms. Grounding clinical recommendations in primary data ensures that patient counseling remains calibrated, safe, and medically sound across all treatment pathways. Evaluating emerging cohort data with clinical discipline ensures that therapeutic decisions remain anchored in verified primary outcomes rather than unmonitored commercial trends. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicCurated updates on Pharmacovigilance in medical cannabis therapy amon. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42787287/) A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us Across these 3 publications, primary findings reveal that This study assessed pharmacovigilance knowledge, adverse drug reaction (ADR) reporting practice and attitudes toward medical cannabis among physicians in Poland, with particular attention to factors associated with ADR reporting. Crude associations were examined using chi-square tests, Fisher’s exact tests for cannabis-specific sparse-data comparisons, Cramer’s V, odds ratios (ORs) and 95% confidence intervals, with Benjamini-Hochberg false-discovery-rate adjustment. Most respondents reported clinical exposure to medical cannabis (81.0%), whereas only 13.4% reported adequate formal education in this area. Evaluating these outcomes alongside Determination of cadmium, lead and mercury in provides quantified benchmarks for clinical observation rather than relying on unverified claims. Why This Matters Tracking verified cohort outcomes across 3 distinct clinical and public-health reports ensures clinicians, registered patients, and families can evaluate therapeutic applications while prioritizing harm reduction and product safety. Study SnapshotPost TypeCannabis News and Regulatory Roundup using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesSeptember 25, 2026Related Reading3 verified live CED Clinic internal linksStudy 1Pharmacovigilance in medical cannabis th (Kopciuch et al., PubMed) [DOI: 10.3389/fpubh.2026.1915903 | PMID: 42787287]Study 2Determination of cadmium, lead and mercu (Pereira et al., PubMed) [DOI: 10.1093/jaoacint/qsag088 | PMID: 42786586]Study 3Cannabinoids as Context-Dependent Modula (Serrano-Marín et al., PubMed) [DOI: 10.1016/j.phrs.2026.109641 | PMID: 42785538] Clinical Bottom Line This cannabis news and regulatory roundup preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Digest Contents - [Digest Card 1 | Pharmacovigilance in medical cannabis therapy amon](#digest-card-2-digest-card-1-pharmacovigilance-in-medical-cannabis-therapy-amon) - [Digest Card 2 | Determination of cadmium, lead and mercury in cann](#digest-card-3-digest-card-2-determination-of-cadmium-lead-and-mercury-in-cann) - [Digest Card 3 | Cannabinoids as Context-Dependent Modulators of th](#digest-card-4-digest-card-3-cannabinoids-as-context-dependent-modulators-of-th) Why These 3 Updates Belong Together This curated cannabis news and regulatory roundup brings together 3 key developments across policy, market milestones, and health regulations. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report. Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision. Digest Card 1 | Pharmacovigilance in medical cannabis therapy amon **Title & Source:** [Pharmacovigilance in medical cannabis therapy among physicians in Poland: pharmacovigilance knowledge, ADR reporting practice and cannabis-related safety reporting.](https://pubmed.ncbi.nlm.nih.gov/42787287/) (*PubMed*, 2026) **Lead Authors & Identifiers:** Dorota Kopciuch, Agata Kapcińska, Krzysztof Kus, Emilio Russo. | **Primary Record:** DOI: 10.3389/fpubh.2026.1915903 | PMID: 42787287 Content lane: **Safety Signal**. **1. Scientific & Clinical Background:** Investigating Pharmacovigilance in medical cannabis therapy among physicians in Poland: pharmacovigilance knowledge, ADR reporting practice and cannabis-related safety reporting., researchers evaluated Medical cannabis is increasingly used in routine care, but its pharmacovigilance profile remains difficult to monitor because products, formulations, doses, routes of administration and clinical indications vary substantially. This study assessed pharmacovigilance knowledge, adverse drug reaction (ADR) reporting practice and attitudes toward medical cannabis among physicians in Poland, with particular attention to factors associated with ADR reporting. **2. Detailed Findings & Primary Data:** Primary observations demonstrated that This study assessed pharmacovigilance knowledge, adverse drug reaction (ADR) reporting practice and attitudes toward medical cannabis among physicians in Poland, with particular attention to factors associated with ADR reporting. Crude associations were examined using chi-square tests, Fisher’s exact tests for cannabis-specific sparse-data comparisons, Cramer’s V, odds ratios (ORs) and 95% confidence intervals, with Benjamini-Hochberg false-discovery-rate adjustment. Most respondents reported clinical exposure to medical cannabis (81.0%), whereas only 13.4% reported adequate formal education in this area. **3. Dr. Caplan’s Clinical & Practical Guidance:** The observational findings support practical, therapy-specific pharmacovigilance training but should not be interpreted causally. In practical terms, these data offer a useful baseline for evaluating realistic therapeutic expectations. **4. Study Boundaries & Methodological Limits:** These outcomes must be interpreted within the specific design parameters and cohort bounds of Pharmacovigilance in medical cannabis therapy among physicians in Poland: pharmacovigilance knowledge, ADR reporting practice and cannabis-related safety reporting. before generalizing broadly. Digest Card 2 | Determination of cadmium, lead and mercury in cann **Title & Source:** [Determination of cadmium, lead and mercury in cannabis flowers by microwave plasma atomic emission spectrometry.](https://pubmed.ncbi.nlm.nih.gov/42786586/) (*PubMed*, 2026Sep24) **Lead Authors & Identifiers:** Mónica Pereira, Ignacio Machado, Florencia Tissot. | **Primary Record:** DOI: 10.1093/jaoacint/qsag088 | PMID: 42786586 Content lane: **Evidence Check**. **1. Scientific & Clinical Background:** Investigating Determination of cadmium, lead and mercury in cannabis flowers by microwave plasma atomic emission spectrometry., researchers evaluated The rapid expansion of legal medicinal and recreational cannabis markets has increased the need for quality control strategies and regulatory monitoring of contaminants in cannabis products. Toxic elements are of particular concern because cannabis plants can accumulate trace metals from environmental and cultivation sources. **2. Detailed Findings & Primary Data:** Primary observations demonstrated that The rapid expansion of legal medicinal and recreational cannabis markets has increased the need for quality control strategies and regulatory monitoring of contaminants in cannabis products. Accuracy was evaluated using reference materials and spiked samples, with recoveries of 95-101% and 81-90%, respectively, and relative standard deviations below 15%. **3. Dr. Caplan’s Clinical & Practical Guidance:** The proposed methodologies represent a practical, cost-effective, and sustainable alternative to argon-based plasma techniques for routine quality control and compliance testing of cannabis products. In practical terms, these data offer a useful baseline for evaluating realistic therapeutic expectations. **4. Study Boundaries & Methodological Limits:** These outcomes must be interpreted within the specific design parameters and cohort bounds of Determination of cadmium, lead and mercury in cannabis flowers by microwave plasma atomic emission spectrometry. before generalizing broadly. Digest Card 3 | Cannabinoids as Context-Dependent Modulators of th **Title & Source:** [Cannabinoids as Context-Dependent Modulators of the Adenosine A3 Receptors: Potential Orthosteric and Allosteric Mechanisms.](https://pubmed.ncbi.nlm.nih.gov/42785538/) (*PubMed*, 2026Sep24) **Lead Authors & Identifiers:** Joan Serrano-Marín, Gemma Navarro, Verónica Sánchez de Medina, Carlos Ferreiro-Vera, Jaume Lillo, Rafael Franco. | **Primary Record:** DOI: 10.1016/j.phrs.2026.109641 | PMID: 42785538 Content lane: **Safety Signal**. **1. Scientific & Clinical Background:** Investigating Cannabinoids as Context-Dependent Modulators of the Adenosine A3 Receptors: Potential Orthosteric and Allosteric Mechanisms., researchers evaluated Adenosine regulates neurotransmission, immunity, inflammation, and tissue protection via four G protein-coupled receptors, among which the adenosine A3 receptor (A3R) remains comparatively understudied despite its therapeutic promise. This study examined whether cannabidiol (CBD) and cannabigerol (CBG) modulate human A3R signalling, alone or with added adenosine, using cAMP assays, molecular docking, binding-energy calculations, and molecular dynamics simulations. **2. Detailed Findings & Primary Data:** Primary observations demonstrated that In the presence of 100nM CBD, the apparent IC50 of adenosine decreased from 138 to 42nM, whereas 100nM CBG reduced it to 1.0nM, corresponding to an approximately 138-fold increase in apparent adenosine potency; CBG also increased the maximal inhibitory response. **3. Dr. Caplan’s Clinical & Practical Guidance:** Further work, encompassing direct binding studies, proximal signalling assays, receptor-subtype profiling, and structural analyses, is needed to validate this mechanism. In practical terms, these data offer a useful baseline for evaluating realistic therapeutic expectations. **4. Study Boundaries & Methodological Limits:** These outcomes must be interpreted within the specific design parameters and cohort bounds of Cannabinoids as Context-Dependent Modulators of the Adenosine A3 Receptors: Potential Orthosteric and Allosteric Mechanisms. before generalizing broadly. How Strong Is This Evidence? Evidence across these 3 records reflects primary reporting from PubMed. While cohorts provide valuable observational and mechanistic data on Pharmacovigilance in medical cannabis therapy amon, prospective comparative trials are needed to validate therapeutic application. Where This Paper Deserves Skepticism Findings in Pharmacovigilance in medical cannabis therapy depend on the specific retrospective or observational methodology used, which carries inherent risks of unmeasured confounding and reporting bias across differing clinical sites. What This Paper Does Not Show These reports do not establish definitive clinical efficacy across unstudied patient subgroups, nor do they replace comprehensive physician evaluation and personalized medical supervision. How This Fits With the Broader Clinical Conversation Clinical research and regulatory oversight concerning Pharmacovigilance in medical cannabis therapy amon continue to advance through detailed peer-reviewed investigations. Evaluating multi-source clinical evidence helps healthcare providers and patients understand therapeutic mechanisms while remaining attentive to safety boundaries. Dr. Caplan’s Take *When looking at the numbers behind pharmacovigilance in medical cannabis therapy among, the most meaningful takeaway is rarely just the headline statistic. It comes down to how these outcomes translate into daily life, symptom relief, and manageable routines for individuals.* *Evidence like this is valuable because it gives us concrete reference points rather than guesswork. The next step is always looking past the initial promise to see how consistent the tolerability and long-term stability prove to be across diverse patient groups.* What a Careful Reader Should Take Away When evaluating developments in Pharmacovigilance in medical cannabis therapy, focus on verified primary data and discuss potential clinical implications with a qualified physician. Evidence Interpretation Guide Table of Contents - [How to Interpret This Cannabis News and Regulatory Roundup](#How_to_Interpret_This_Cannabis_News_and_Regulatory_Roundup)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[Focus on Practical Realities and Safe Access](#Focus_on_Practical_Realities_and_Safe_Access) - [Incorporate Primary Evidence Into Counseling](#Incorporate_Primary_Evidence_Into_Counseling) - [Prioritize Tested Formulations and Safe Storage](#Prioritize_Tested_Formulations_and_Safe_Storage) - [Track Real-World Implementation Timelines](#Track_Real-World_Implementation_Timelines) - [Demand Controlled Designs and Cohort Studies](#Demand_Controlled_Designs_and_Cohort_Studies) - [Separate Primary Data from Headline Framing](#Separate_Primary_Data_from_Headline_Framing) - [Maintain Safe Storage and Clear Routines](#Maintain_Safe_Storage_and_Clear_Routines) - [A Grounded and Evidence-Based Overview](#A_Grounded_and_Evidence-Based_Overview) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Cannabis News and Regulatory Roundup Navigating updates on Pharmacovigilance in medical cannabis therapy amon requires reviewing primary study designs and clinical context. ### Three Rules for Critical Reading **Evaluate Study Design**Check whether the reported findings in Pharmacovigilance in medical cannabis th stem from controlled trials, observational cohorts, or laboratory models. **Assess Cohort Boundaries**Analyze whether sample sizes and participant demographics represent the broader patient population seeking care. **Engage Clinical Guidance**Discuss therapeutic decisions with a knowledgeable healthcare professional before modifying treatment plans. Key Evaluation Question Do the findings in Pharmacovigilance in medical cannabis therapy provide actionable clinical guidance or preliminary observational data? The Patient Question How do the specific outcomes reported here affect my current care plan or symptom management? The Bottom Line Careful appraisal of Pharmacovigilance in medical cannabis therapy ensures grounded and safe clinical decision-making. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight distinct clinical and regulatory perspectives on Pharmacovigilance in medical cannabis therapy. #### Focus on Practical Realities and Safe Access Patients reviewing these updates should recognize that scientific literature describes broader population trends rather than individual prescriptions. Discussing new therapeutic options with a knowledgeable physician ensures safe and personalized care. Understanding product testing, certified licensing, and proper administration methods helps patients avoid misleading commercial claims while protecting their personal health. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayVerified clinical information empowers patients to make grounded and safe medical decisions every day. #### Incorporate Primary Evidence Into Counseling Healthcare providers benefit from tracking peer-reviewed studies because patient inquiries often reflect recent publications. Clinicians who review the underlying data can offer balanced, evidence-informed guidance. Maintaining open discussions regarding dosing ratios, product purity, and potential medication interactions strengthens the therapeutic relationship and elevates patient safety. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayGrounded awareness of newly published literature enhances the quality of routine patient care. #### Prioritize Tested Formulations and Safe Storage Product safety remains central to patient well-being. Rigorous laboratory testing for contaminants and accurate cannabinoid labeling protect vulnerable patients from unexpected adverse effects. Standardized packaging, child-resistant containers, and clear storage protocols are essential safeguards that deserve universal clinical reinforcement across all communities. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayUncompromising testing standards and transparent product labeling are fundamental prerequisites for patient safety. #### Track Real-World Implementation Timelines Regulatory guidelines and clinical advisories represent vital steps in protecting public health. Administrative rulemaking determines how testing standards and access rules translate into everyday patient care. Monitoring public health agencies as they update consumer advisories helps clinicians anticipate regional healthcare needs and guide patients appropriately. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayEffective implementation and transparent oversight govern the real-world success of progressive healthcare policy. #### Demand Controlled Designs and Cohort Studies Retrospective surveys and preliminary laboratory findings generate valuable hypotheses but cannot replace prospective, randomized investigations. Advancing the field requires rigorous methodology and objective endpoints. Expanding clinical research funding and standardized outcome tracking will clarify specific cannabinoid mechanisms and therapeutic boundaries across diverse patient populations. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayMethodologically rigorous prospective investigations are essential to convert scientific signals into established clinical practice. #### Separate Primary Data from Headline Framing A disciplined medical reading requires separating commercial marketing from verified scientific data. Media headlines frequently exaggerate preliminary associations while overlooking cohort limitations. Applying consistent critical appraisal protects clinicians and patients from adopting premature conclusions before treatments are thoroughly validated. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayRigorous critical appraisal protects both clinicians and patients from confusing promotional marketing with reproducible evidence. #### Maintain Safe Storage and Clear Routines Caregivers supporting patients using medical cannabis require clear instructions regarding storage, administration schedules, and safety precautions. Keeping products securely stored prevents unintended pediatric or household exposures. Open communication among family members, caregivers, and certifying physicians fosters a supportive environment that enhances treatment safety and patient comfort. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawaySecure product storage and transparent communication establish a safe, supportive environment for patient care. #### A Grounded and Evidence-Based Overview Progress across clinical research occurs through steady, incremental milestones rather than sudden breakthroughs. Synthesizing multiple investigations provides a realistic picture of current evidence. Keeping clinical expectations anchored in primary data enables physicians and patients to make sound healthcare choices that promote long-term well-being. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayGrounded understanding and rigorous evaluation of verified facts serve the long-term interests of patients and clinicians. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+News+and+Regulatory+Roundup%3A+Pharmacovigilance+in+medical+cannabis+therap...&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-pharmacovigilance-in-medical-cannab-sep-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-pharmacovigilance-in-medical-cannab-sep-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+News+and+Regulatory+Roundup%3A+Pharmacovigilance+in+medical+cannabis+therap...%20https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-pharmacovigilance-in-medical-cannab-sep-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: PubMed, PubMed, PubMed](https://pubmed.ncbi.nlm.nih.gov/42787287/) Related Reading at CED ClinicContinue exploring the evidence[CBD or THC: Sorting the Claimed Advantages by What Randomized Trials Have Shown](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/) More on this topic: Direct comparison of THC and CBD analgesic pathways and evidence-supported clinical indications. [More on this topic: CBD vs THC for pain](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/)[THC Testing After Childbirth Can Trigger Child-Welfare Consequences](https://cedclinic.com/thc-testing-new-mothers-child-welfare/) More on this topic: Evidence-based breakdown of perinatal drug screening, hospital reporting policies, and downstream child protective services involvement. [More on this topic: Perinatal screening & welfare](https://cedclinic.com/thc-testing-new-mothers-child-welfare/)[NY Times Response: Teens and Strong Cannabis](https://cedclinic.com/high-potency-cannabis-risks/) More on this topic: Critical discussion of high-potency THC products, youth exposure risks, and clinical communication with teens. [More on this topic: Youth & potency risks](https://cedclinic.com/high-potency-cannabis-risks/) ## Frequently Asked Questions What is covered in this cannabis news and regulatory roundup? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact patient access? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with medical cannabis at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).